David O'Malley, MD | Authors

Articles

SITC 2021 Updates for Cervical Cancer: AGEN1181

December 17, 2021

David M. O’Malley, MD, shares insight on data presented at SITC 2021 on the use of a second-generation, Fc-enhanced anti-CTLA4 antibody, AGEN1181, in patients with advanced cervical cancer as well as other solid tumors.